Our Publications

The full list of publications we can be found at www.ncbi.nlm.nih.gov/pubmed/.
For more information about any publication please contact us.


Duygu B, Poels EM, Juni R, Bitsch N, Ottaviani L, Olieslagers S, De Windt LJ, da Costa Martins PA. miR-199b-5p is a regulator of left ventricular remodeling following myocardial infarction. Non-coding RNA Research. 2017;2:18-26.

Zucker IH, Lindsey ML, Delmar M, De Windt LJ, Des Rosiers C, Diz DI, Hester RL, Jones SP, Kanagy NL, Kitakaze M, Liao R, Lopaschuk GD, Patel KP, Recchia FA, Sadoshima J, Shah AM, Ungvari ZI, Benjamin IJ, Blaustein MP, Charkoudian N, Efimov IR, Gutterman DD, Kass DA, Liao Y, O\'Leary DS, Ripplinger CM, Wolin MS. Why Publish in the American Journal of Physiology-Heart and Circulatory Physiology? Am J Physiol Heart Circ Physiol. 2017 doi: 10.1152/ajpheart.00329.2017

Raso A, Dirkx E. Cardiac Regenerative Medicine: At the crossroad of microRNA function and biotechnology. Non-coding RNA Research. 2017;2:27-37.

Calore M. Editorial Focus on H-00813-2016R1 PRKAG2 gene and hypertrophic cardiomyopathy: an energetically imbalanced relationship. Am J Physiol Heart Circ Physiol. 2017 doi: 10.1152/ajpheart.00316.2017.

Ottaviani L, da Costa Martins PA. Non-coding RNAs in cardiac hypertrophy. J Physiol. 2017;595:4037-4050.

Lorenzon A, Calore M, Poloni G, De Windt LJ, Braghetta P, Rampazzo A. Wnt/β-catenin pathway in arrhythmogenic cardiomyopathy. Oncotarget. 2017 Apr 27. doi: 10.18632/oncotarget.17457.

Mohseni Z, Spaanderman MEA, Oben J, Calore M, Derksen E, Al-Nasiry S, de Windt LJ, Ghossein-Doha C. Cardiac remodelling and preeclampsia: an overview of overlapping miRNAs. Ultrasound Obstet Gynecol. 2017 May 3. doi: 10.1002/uog.17516.

Perrino C, Barabási AL, Condorelli G, Davidson SM, De Windt L, Dimmeler S, Engel FB, Hausenloy DJ, Hill JA, Van Laake LW, Lecour S, Leor J, Madonna R, Mayr M, Prunier F, Sluijter JPG, Schulz R, Thum T, Ytrehus K, Ferdinandy P. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2017;113:725-736.

Ghossein-Doha C, van Neer J, Wissink B, Breetveld NM, de Windt LJ, van Dijk AP, van der Vlugt MJ, Janssen MC, Heidema WM, Scholten RR, Spaanderman ME. Pre-eclampsia: an important risk factor for asymptomatic heart failure. Ultrasound Obstet Gynecol. 2017 ;49(1):143-149.

Momken I, Chabowski A, Dirkx E, Nabben M, Jain SS, McFarlan JT, Glatz JF, Luiken JJ, Bonen A. A new leptin-mediated mechanism for stimulating fatty acid oxidation: a pivotal role for sarcolemmal FAT/CD36. Biochem J. 2017;474:149-162.


Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016;18:457-468.

Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S, Thum T. Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med. 2016;8(326):326ra22.

Peters T, Hermans-Beijnsberger S, Beqqali A, Bitsch N, Nakagawa S, Prasanth KV, de Windt LJ, van Oort RJ, Heymans S, Schroen B. Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice. PLoS One. 2016;11(2):e0150236.

Ottaviani L, De Windt LJ, da Costa Martins PA. Exosomes: scytales in the damaged heart. Ann Transl Med. 2016;4:222.

Poloni G, De Bortoli M, Calore M, Rampazzo A, Lorenzon A. Arrhythmogenic right-ventricular cardiomyopathy: molecular genetics into clinical practice in the era of next generation sequencing. J Cardiovasc Med (Hagerstown). 2016;17:399-407.

Janssen R, Zuidwijk MJ, Muller A, van Mil A, Dirkx E, Oudejans CB, Paulus WJ, Simonides WS. MicroRNA 214 Is a Potential Regulator of Thyroid Hormone Levels in the Mouse Heart Following Myocardial Infarction, by Targeting the Thyroid-Hormone-Inactivating Enzyme Deiodinase Type III. Front Endocrinol (Lausanne). 2016;7:22.

Gupta SK, Foinquinos A, Thum S, Remke J, Zimmer K, Bauters C, de Groote P, Boon RA, de Windt LJ, Preissl S, Hein L, Batkai S, Pinet F, Thum T. Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. J Am Coll Cardiol. 2016;68:1557-1571.


Azzouzi HE, Leptidis S, Doevendans PA, De Windt LJ. HypoxamiRs: regulators of cardiac hypoxia and energy metabolism. Trends Endocrinol Metab. 2015. doi: 10.1016/j.tem.2015.06.008.

Cannon MV, Silljé HH, Sijbesma JW, Vreeswijk-Baudoin I, Ciapaite J, van der Sluis B, van Deursen J, Silva GJ, de Windt LJ, Gustafsson JÅ, van der Harst P, van Gilst WH, de Boer RA. Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med. 2015;7(9):1229-1243.

Duygu B, de Windt LJ, da Costa Martins PA. Targeting microRNAs in heart failure. Trends Cardiovasc Med. 2015. doi: 10.1016/j.tcm.2015.05.008.

Poels EM, da Costa Martins PA, van Empel VP. Adaptive capacity of the right ventricle: why does it fail? Am J Physiol Heart Circ Physiol. 2015;308(8):H803-813.

Philippen LE, Dirkx E, da Costa Martins PA, De Windt LJ. Non-coding RNA in control of gene regulatory programs in cardiac development and disease. J Mol Cell Cardiol. 2015. doi: 10.1016/j.yjmcc.2015.03.014.


Leite-Moreira AF, Lourenco AP, Balligand JL, Bauersachs J, Clerk A, De Windt LJ, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Kaminski KA, Knoll R, Mayr M, Tarone G, Thum T, Tocchetti CG. ESC Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. Eur J Heart Fail. 2014;16(5):509-518. [IF= 6.6]

Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knoll R, Leite-Moreira AF, Lourenco AP, Mayr M, Thum T, Tocchetti CG. Targeting myocardial remodelling to develop novel therapies for heart failure: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014;16(5):494-508. [IF= 6.6]

Roncarati R, Anselmi CV, Losi MA, Papa L, Cavarretta E, Costa Martins PD, Jotti GS, Franzone A, Galastri L, Latronico MV, Imbriaco M, Esposito G, De Windt L, Betocchi S, Condorelli G. Circulating miR-29a, Among Other Upregulated microRNAs, is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients with Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2014;63(9):920-927. [IF= 14.7]

Poels EM, Bitsch N, Slenter JM, Kooi ME, de Theije CC, de Windt LJ, van Empel VP, da Costa Martins PA. Supplementing exposure to hypoxia with a copper depleted diet does not exacerbate right ventricular remodeling in mice. PLOS One. 2014;9(4):e92983. [IF= 3.7]

da Costa Martins PA, Leptidis S, De Windt LJ. Nuclear calcium transients: Hermes Propylaios in the heart. Circulation. 2014;130(3):221-223. [IF= 15.2]


De Windt LJ, Doevendans PA. Towards modern genetics, diagnostics and therapeutics of heart failure in a new era. BBA-Mol Basis Dis. 2013;1832:2401-2402. [IF= 5.4]

Halkein J, De Windt LJ. miR-223: sailing to terra incognita for microRNAs in platelets. Thromb Haemostasis. 2013;110:1112-1113 [IF= 5.0]

Kinet V, Halkein J, Dirkx E, De Windt LJ. Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Front Genet. 2013;4:214.

Dirkx E, Gladka MM, Philippen LE, Armand AS, Kinet V, Leptidis S, El Azzouzi H, Salic K, Bourajjaj M, da Silva GJ, Olieslagers S, van der Nagel R, de Weger R, Bitsch N, Kisters N, Seyen S, Morikawa Y, Chanoine C, Heymans S, Volders PG, Thum T, Dimmeler S, Cserjesi P, Eschenhagen T, da Costa Martins PA, De Windt LJ. Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol. 2013;15:1282-1293. [IF= 19.5]

Dirkx E, da Costa Martins PA, De Windt LJ. Regulation of fetal gene expression in heart failure. BBA-Mol Basis Dis. 2013;1832:2414-2424. [IF= 5.4]

Kuster DW, Mulders J, Ten Cate FJ, Michels M, Dos Remedios CG, da Costa Martins PA, van der Velden J, Oudejans CB. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. J Mol Cell Cardiol. 2013;65:59-66 [IF= 5.2].

Lok SI, van Mil A, Bovenschen N, van der Weide P, van Kuik J, van Wichen D, Peeters T, Siera E, Winkens B, Sluijter JP, Doevendans PA, da Costa Martins PA, de Jonge N, de Weger RA Post-transcriptional Regulation of α-1-Antichymotrypsin by MicroRNA-137 in Chronic Heart Failure and Mechanical Support. Circ Heart Fail. 2013 Jul;6(4):853-861.l [IF= 6.6]

Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, Silva GJ, Heymans S, Cuppen E, Berezikov E, De Windt LJ, da Costa Martins P. A Deep Sequencing Approach to Uncover the miRNOME in the Human Heart. PLoS One. 2013;8(2):e57800 [IF= 4.4]

Hirsch E, Hilfiker-Kleiner D, Balligand JL, Tarone G, De Windt L, Bauersachs J, Ferdinandy P, Davidson S, Hausenloy DJ, Schulz R. Interaction of the heart and its close and distant neighbours: report of the Meeting of the ESC Working Groups Myocardial Function and Cellular Biology. Cardiovasc Res. 2013;99(4):595-599. [IF = 5.9]

Tritsch E, Mallat Y, Lefebvre F, Diguet N, Escoubet B, Blanc J, De Windt LJ, Catalucci D, Vandecasteele G, Li Z, Mericskay M. : An SRF/miR-1 axis regulates NCX1 and Annexin A5 protein levels in the normal and failing heart. Cardiovasc Res. 2013;98:372-380. [IF= 6.1]

Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, St�ger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Sch�rmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, De Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B. Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure. Circulation. 2013 ;128(13):1420-1432. [IF= 15.2]

El Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K, McClellan EA, Poels E, Sluimer JC, van den Hoogenhof MM, Armand AS, Yin X, Langley S, Bourajjaj M, Olieslagers S, Krishnan J, Vooijs M, Kurihara H, Stubbs A, Pinto YM, Krek W, Mayr M, da Costa Martins PA, Schrauwen P, De Windt LJ. The Hypoxia-Inducible MicroRNA Cluster miR-199a∼214 Targets Myocardial PPARδ and Impairs Mitochondrial Fatty Acid Oxidation. Cell Metab. 2013;18(3):341-354. [IF=17.55]


Kinet V, Dirkx E, De Windt LJ. Quaero muneris: Exploring microRNA function in cardiovascular disease. J Mol Cell Cardiol. 2012;51:1-2. I [IF= 5.5] I

Heijman J, Sp?§tjens RL, Seyen SR, Lentink V, Kuijpers HJ, Boulet IR, de Windt LJ, David M, Volders PG. Dominant-Negative Control of cAMP-Dependent IKs Upregulation in Human Long-QT Syndrome Type 1. Circ Res. 2012;110:211-219. I [IF= 9.5] I

Gladka MM, Da Costa Martins PA, De Windt LJ. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol. 2012;52:74-82. I [IF= 5.5] I

Da Costa Martins PA, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res. 2012;93:563-572. I [IF= 6.1] I

Salic K, De Windt LJ. MicroRNAs as biomarkers for myocardial infarction. Curr Atheroscler Rep. 2012;14:193-200. I [IF= 2.5] I

el Azzouzi H, Leptidis S, Bourajjaj M, van Bilsen M, da Costa Martins PA, De Windt LJ. MEK1 inhibits cardiac PPARa activity by direct interaction and prevents its nuclear localization. Plos One. 2012;7(6):e36799. I [IF= 4.4] I

Bourgonje VJA, Schoenmakers M, Beekman JDM, van der Nagel R, Houtman MJC, Miedema LF, Antoons G, Sipido K, de Windt LJ, van Veen TAB, Vos MA. Relevance of Calmodulin/CaMKII Activation for Arrhythmogenesis in the AV-Block Dog. Heart Rhythm. 2012;9(11):1875-1883. I [IF= 4.1] I

Da Costa Martins PA, De Windt LJ. Targeting MicroRNA targets. Circ Res. 2012;111:506-508. I [IF= 9.5] I

van Empel VP, De Windt LJ, da Costa Martins PA. Circulating miRNAs: reflecting or affecting cardiovascular disease? Curr Hypertens Rep. 2012;14(6):498-509. I [IF= 2.5] I


el Azzouzi H, Leptidis S, Bourajjaj M, Armand AS, van der Nagel R, van Bilsen M, da Costa Martins PA, De Windt LJ. PPAR gene profiling uncovers insulin-like growth factor-1 (IGF1) as a PPAR-alpha target gene in cardioprotection. J Biol Chem. 2011;286:14598-14607. I [IF= 5.3] I

Bartelds B, Borgdorff MA, Smit-van Oosten A, Takens J, Boersma B, Nederhoff MG, Elzenga NJ, van Gilst WH, de Windt LJ, Berger RM. Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load. Eur J Heart Fail. 2011;13:1275-1282. I [IF= 4.5] I

Armand AS, Laziz I, Djeghloul D, L?©colle S, Bertrand A, Biondi O, De Windt LJ, Chanoine C. Apoptosis-Inducing Factor regulates skeletal muscle progenitor cell number and self-renewal. Plos One. 2011;6(11):e27283. I [IF= 4.4] I


den Hengst WA, Gielis JF, Lin JY, Van Schil PE, De Windt LJ, Moens AL. Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol. 2010;229;H1283-1299. I IF= 3.6 I

van Rooij E, Fielitz J, Sutherland LB, Thijssen VL, Crijns HJ, Dimaio MJ, Shelton J, De Windt LJ, Hill JA, Olson EN. MEF2 and class II HDACs control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res. 2010;106:155-165. I IF= 10.0 I

el Azzouzi H, van Oort RJ, van der Nagel R, Bergmann MW, De Windt LJ. MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload. Eur J Heart Fail. 2010;12:4-12. I IF= 3.4 I

van Oort RJ, Respress JL, Sarma S, Reynolds C, Skapura DG, De Windt LJ, Wehrens XHT. Accelerated development of pressure overload-induced cardiac hypertrophy in a RyR2-R176Q knockin mouse model. Hypertension. 2010;55:932-938. I IF= 7.4 I

Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035-1039. I IF= 10.0 I

da Costa Martins PA, Leptidis S, Salic K, De Windt LJ. microRNA regulation in cardiovascular disease. Curr Drug Targets. 2010;11(8):900-906. I IF= 4.2 I

da Costa Martins PA, De Windt LJ. miR-21: a miRaculous Socratic paradox. Cardiovasc Res. 2010;87(3):397-400. I IF= 6.1 I

Leenders JJ, Wijnen WJ, Hiller M, van der Made I, Lentink V, van Leeuwen RE, Herias V, Pokharel S, Heymans S, de Windt LJ, Hoydal MA, Pinto YM, Creemers EE. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J Biol Chem. 2010;285:27449-27456. I IF= 5.5 I

da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der Nagel R, van Kuik J, de Weger R, de Bruin A, Condorelli G, Arbones ML, Eschenhagen T, De Windt LJ. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto amplification loop promoting calcineurin/NFAT signaling. Nature Cell Biol. 2010;12(12):1220-1227. I IF= 19.6 I


Gladka M, el azzouzi H, De Windt LJ, da Costa Martins PA. Aquaporin 7: the glycerol aquaeductus in the heart. Cardiovasc Res. 2009;83:3-4. I IF=6.1 I

Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, Dietz R, de Windt L, Bergmann MW. NF-kB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res. 2009 In Press I IF=6.1 I


Zelaray?°n L, Noack C, Sekkali B, Kmecova J, Gehrke C, Renger A, Zafiriou MP, van der Nagel R, Dietz R, De Windt LJ, Balligand JL, Bergmann MW. b-catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci USA. 105(50):19762-19767 I IF=9.6 I

da Costa Martins PA, De Windt LJ. Nix: the cardiac Styx between survival and death. Circulation 2008;177(3):338-340. I IF=12.8 I

Karatas A, Hegner B, De Windt LJ, Luft FC, Schubert C, Gross V, Akashi YJ, Gurgen D, Kintscher U, da Costa Goncalves AC, Regitz-Zagrosek V, Dragun D. Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. Hypertension 2008;51:1-7. I IF=7.3 I

el Azouzzi H, De Windt LJ. Heart spotting. Basic Res Cardiol 2008;103:228-231. I IF=3.8 I

Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XT, De Windt LJ. NFATc2 is required in calcineurin-mediated cardiac hypertrophy and heart failure. J Biol Chem. 2008;283:22295-22303. I IF=5.6 I

Bierhuizen MFA, Boulaksil M, van Stuijvenberg L, van der Nagel R, Jansen AT, Mutsaers NAM, Yildirim C, van Veen TAB, De Windt LJ, Vos MA, van Rijen HVM. In calcineurin-induced cardiac hypertrophy the expression of Nav1.5, Cx40 and Cx43 is reduced by different mechanisms. J Mol Cell Cardiol. 2008;45:373-384 I IF=4.9 I

Armand AS, Bourajjaj M, Martinez-Martinez S, da Costa Martins PA, Hatzis P, Seidler T, Redondo JM, De Windt LJ. Cooperative synergy between NFAT and MyoD regulates myogenin expression and myogenesis. J Biol Chem. 2008;283:29004-29010 I IF=5.6 I

da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM, Molkentin JD, De Windt LJ. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation. 2008;118:1567-1576 I IF=12.8 I Editorial


Meijs MF, De Windt LJ, de Jonge N, Cramer MJ, Bots ML, Mali WP, Doevendans PA. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem. 2007;14(2):157-171. I IF=4.9 I

Naseem RH, Meeson AP, Dimaio JM, White MD, Kallhoff JB, Humphries CG, Goetsch SC, De Windt LJ, Williams MA, Garry MG, Garry DJ. Reparative myocardial mechanisms in adult C57BL/6 and MRL mice following injury. Physiol Genomics. 2007;30(1):44-52. I IF=3.5 I

Fielitz J, van Rooij E, Spencer JA, Shelton JM, Latif S, van der Nagel R, Bezprozvannaya S, De Windt LJ, Richardson JA, Bassel-Duby R, Olson EN. Requirement of MuRF3 for maintanance of cardiac integrity following myocardial infarction. Proc Natl Acad Sci USA 2007;104:4377-4382. I IF=9.6 I

Bergmann MW, De Windt LJ. Linking cardiac mechanosensing at the sarcomere M-band, NF-κB signaling and cardiac hypertrophy. Hypertension 2007;49(6):1225-1227. I IF=7.3 I

Theunissen BEJ, Smeets PJH, Willemsen PH, De Windt LJ, Van Der Vusse GJ, Van Bilsen M. Activation of PPAR-delta inhibitis cardiac fibroblast proliferation and the differentiation to myofibroblasts. Cardiovasc Res. 2007; 75(3):519-29. I IF=6.1 I


de Jonge N, Goumans MJ, Lips D, Hassink R, Vlug EJ, van der Meel R, Emmerson CD, Nijman J, De Windt L, Doevendans PA. Controlling cardiomyocyte survival. Novartis Found Symp. 2006;274:41-51. I

Sanna B, Brandt EB, Kaiser RA, Pfluger P, Witt SA, Kimball TR, van Rooij E, De Windt LJ, Rothenberg ME, Tschop MH, Benoit SC, Molkentin JD. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A. 2006;103(19):7327-7332. I IF=9.6 I

van Empel VP, Bertrand AT, van Oort RJ, van der Nagel R, Engelen M, van Rijen HV, Doevendans PA, Crijns HJ, Ackerman SL, Sluiter W, De Windt LJ. EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and ameliorates pressure overload-induced heart failure in the harlequin mouse mutant. J Am Coll Cardiol. 2006;48(4):824-832. I IF=11.1 I

van Oort RJ, van Rooij E, Bourajjaj M, Schimmel J, Jansen MA, van der Nagel R, Doevendans PA, Schneider MD, van Echteld CJ, De Windt LJ. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation. 2006;114(4):298-308. I IF=12.8 I


Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, Godecke A, Baba HA, Kuhn M. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem. 2005;280(22):21594-21599. I IF=5.6 I

Donners MM, Bot I, De Windt LJ, van Berkel TJ, Daemen MJ, Biessen EA, Heeneman S. Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. Am J Transplant. 2005;5(6):1204-1215. I IF=6.4 I

Kilic A, Velic A, De Windt LJ, Fabritz L, Voss M, Mitko D, Zwiener M, Baba HA, van Eickels M, Schlatter E, Kuhn M. Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation. 2005;112(15):2307-2317. I IF=12.8 I

Oh M, Rybkin, II, Copeland V, Czubryt MP, Shelton JM, van Rooij E, Richardson JA, Hill JA, De Windt LJ, Bassel-Duby R, Olson EN, Rothermel BA. Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers. Mol Cell Biol. 2005;25(15):6629-6638. I IF=6.4 I

Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, Gary-Bobo G, De Windt LJ, Ludosky MA, Paulin D, Daegelen D, Tuil D, Li Z. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation. 2005;112(19):2930-2939. I IF=12.8 I

van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005;67(1):21-29. I IF=6.1 I

van Empel VP, Bertrand AT, van der Nagel R, Kostin S, Doevendans PA, Crijns HJ, de Wit E, Sluiter W, Ackerman SL, De Windt LJ. Downregulation of apoptosis-inducing factor in harlequin mutant mice sensitizes the myocardium to oxidative stress-related cell death and pressure overload-induced decompensation. Circ Res. 2005;96(12):e92-e101. I IF=9.7 I

van Oort RJ, De Windt LJ. TOLL-erating cardiac hypertrophy following pressure overload. Cardiovasc Res. 2005;68(2):178-179. I IF=6.1 I

Wehrens XH, Lehnart SE, Reiken S, van der Nagel R, Morales R, Sun J, Cheng Z, Deng SX, De Windt LJ, Landry DW, Marks AR. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci U S A. 2005;102(27):9607-9612. I IF=9.6 I


Van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004;63(3):487-499. I IF=6.1 I

Armand AS, De Windt LJ. Calcium cycling in heart failure: how the fast became too furious. Cardiovasc Res. 2004;62(3):439-441. I IF=6.1 I

Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur J, Pages G, De Windt LJ, Doevendans PA, Molkentin JD. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109(16):1938-1941. I IF=12.8 I

Palmen M, Daemen MJ, De Windt LJ, Willems J, Dassen WR, Heeneman S, Zimmermann R, Van Bilsen M, Doevendans PA. Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism. J Am Coll Cardiol. 2004;44(5):1113-1123. I IF=11.1 I

Lips DJ, van der Nagel T, Steendijk P, Palmen M, Janssen BJ, van Dantzig JM, De Windt LJ, Doevendans PA. Left ventricular pressure-volume measurements in mice: comparison of closed-chest versus open-chest approach. Basic Res Cardiol. 2004;99(5):351-359. I IF=3.8 I

van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res. 2004;94(3):e18-26. I IF=9.7 I

Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohe C, van Bilsen M, Doevendans PA. 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation. 2004;109(2):269-276. I IF=12.8 I